drugset / Trial / NCT03152552

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

NCT03152552

Phase 2 Terminated 125 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure

Timeline

Start
2017-07-25
Primary completion
2018-06-06
Completion
2018-06-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Empagliflozin Small molecule Oral
Subject licogliflozin Small molecule 2.5 mg Oral
Subject licogliflozin Small molecule 10 mg Oral
Subject licogliflozin Small molecule 50 mg Oral